Clinical trialNCT02109224TerminatedPhase 1Interventional

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

SponsorNational Cancer Institute (NCI)Enrollment72Adult B Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaCutaneous B-Cell Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHIV InfectionIntraocular Lymphoma+23 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether it is safe for patients with HIV infection to receive ibrutinib while also taking anti-HIV drugs.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Yvette Kasamon
AIDS Malignancy Consortium
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla Center for Clinical Aids Research and Education
Los Angeles, California, United States
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Siteman Cancer Center at Washington University
St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Albert Einstein College of Medicine
The Bronx, New York, United States
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2014
Primary completion: 31 Jul 2015
Completion: 31 Jul 2015
Last update posted: 20 Aug 2015
Registered enrollment: 72
Registry id: NCT02109224

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.